Equities

Pak Fah Yeow International Ltd

Pak Fah Yeow International Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (HKD)2.65
  • Today's Change-0.01 / -0.38%
  • Shares traded115.00k
  • 1 Year change+86.62%
  • Beta0.2620
Data delayed at least 15 minutes, as of May 22 2024 08:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pak Fah Yeow International Ltd is an investment holding company principally engaged in the manufacture and sale of healthcare products. The Company operates through three segments. The Healthcare segment is engaged in the manufacture and sales of healthcare products under the brand names of Hoe Hin products. The Property Investment segment is engaged in the investment in commercial, office, industrial and residential properties. The Treasury Investment segment is engaged in the equity and debt securities, mutual funds and dual currency investments businesses.

  • Revenue in HKD (TTM)259.16m
  • Net income in HKD105.04m
  • Incorporated1991
  • Employees102.00
  • Location
    Pak Fah Yeow International Ltd11F, 200 Gloucester Road, Wanchai Hong KongHKG
  • Phone+852 28817713
  • Fax+852 25772895
  • Websitehttps://www.pakfahyeow.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kintor Pharmaceutical Ltd0.00-1.14bn545.95m225.00--1.11-----2.66-2.660.001.100.000.1448--0.00-72.55-50.15-89.09-58.43---27.62---10,511.412.10--0.3566-------11.15---32.49--
Clover Biopharmaceuticals Ltd42.33m-149.39m570.70m387.00------13.48-0.1196-0.11960.034-0.60960.01160.00980.7449109,377.70-4.08---16.40--61.75---352.92--0.5281-1.45--------94.35------
Lee's Pharmaceutical Holdings Ltd1.05bn16.70m683.05m1.06k40.900.3354.380.64870.02840.02841.793.460.37131.8310.75996,247.900.703313.330.8817.7652.3561.921.8936.200.55263.900.09433.59-14.61-1.53-67.44-47.49-12.19-31.34
Antengene Corporation Ltd72.58m-626.70m688.39m201.00--0.5564--9.49-1.02-1.020.1181.830.03580.97733.41361,074.00-30.91-53.57-36.46-58.9481.74---863.51-1,987.016.43--0.1491---57.97--3.38------
Sirnaomics Ltd0.00-614.14m712.50m145.00--2.27-----8.08-8.080.003.580.00----0.00-70.91---71.22--------------0.6176------10.88------
Genor Biopharma Holdings Ltd0.00-727.17m748.49m104.00--0.5737-----1.44-1.440.002.540.000.00--0.00-37.91-55.46-44.02-63.73--66.56---14,819.185.38--0.006---100.00--7.65---48.85--
Jbm (Healthcare) Ltd610.30m97.99m800.46m258.008.840.85355.381.310.10870.10870.67861.120.44065.884.102,000,994.007.563.339.044.9347.7045.9717.1710.971.4522.150.121113.8128.1114.51131.906.14-5.09--
Transcenta Holding Limited58.07m-498.80m802.93m215.00--0.7227--13.83-1.23-1.230.14272.550.02812.051.49270,074.80-24.17---33.97--26.74---859.01--1.20-32.870.285---47.15---13.72------
Pak Fah Yeow International Ltd259.16m105.04m828.96m102.007.891.087.373.200.3370.3370.83162.460.29952.8822.182,540,765.0012.143.9912.604.1884.4580.7940.5321.276.9010.080.0062100.6876.0612.94250.6623.0218.83-8.06
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd907.45m159.81m845.98m848.005.290.5306.910.93230.28530.28531.622.850.35872.182.941,070,105.006.327.679.1210.4869.4078.7917.6120.681.51--0.05157.22-0.00495.38-23.43-1.67-1.14--
Zhaoke Ophthalmology Ltd20.22m-415.19m851.98m313.00--0.3857--42.14-0.7634-0.76340.03724.040.0075--0.53164,595.44-15.43---17.27--75.98---2,053.54--5.32-47.540.1041------5.47------
Fusen Pharmaceutical Co Ltd609.90m-39.12m862.45m1.15k--1.42--1.41-0.0524-0.05240.8110.81030.41991.958.36531,274.10-2.690.9678-5.541.7452.9551.95-6.422.590.60960.7560.379727.9515.024.13-4.83--0.2124--
JW (Cayman) Therapeutics Co Ltd187.47m-828.14m974.24m398.00--0.5338--5.20-2.01-2.010.45564.400.07041.6865.54471,033.30-31.11-39.77-35.21-44.0050.74---441.74-1,316.813.86-47.820.1592--19.32--9.23---19.87--
Zhongzhi Pharmaceutical Holdings Ltd2.21bn175.52m993.14m2.64k5.550.87843.450.44930.20720.20722.611.311.122.5310.54836,299.408.957.6914.1511.7559.7360.448.016.730.894--0.142442.4612.2612.4153.0013.8617.653.22
Brii Biosciences Ltd665.32k-188.52m999.84m128.00--0.2971--1,502.80-0.2592-0.25920.00094.610.0002----5,197.81-5.60---5.84-------29,881.69------0.001---98.80--63.90------
Hbm Holdings Ltd698.51m177.92m1.08bn177.005.781.105.031.540.2420.2420.95171.280.38863.903.013,946,381.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61---12.62--
Data as of May 22 2024. Currency figures normalised to Pak Fah Yeow International Ltd's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.